June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Longitudinal Sub-Retinal Pigment Epithelium Disease Burden Assessment in Neovascular Age-Related Macular Degeneration: Results from the OSPREY Study
Author Affiliations & Notes
  • Atsuro Uchida
    The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cleveland Clinic, Cleveland, Ohio, United States
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Julie Clark
    Novartis Pharmaceuticals, East Hanover, New Jersey, United States
  • Robert Zahid
    Novartis Pharmaceuticals, East Hanover, New Jersey, United States
  • Natalia Albuquerque Lucena Figueiredo
    The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cleveland Clinic, Cleveland, Ohio, United States
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Leina Lunasco
    The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cleveland Clinic, Cleveland, Ohio, United States
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Thuy Le
    The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cleveland Clinic, Cleveland, Ohio, United States
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Jamie Reese
    The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cleveland Clinic, Cleveland, Ohio, United States
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Xiang Yi Meng
    Novartis Pharmaceuticals, East Hanover, New Jersey, United States
  • Sunil K Srivastava
    The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cleveland Clinic, Cleveland, Ohio, United States
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Justis Ehlers
    The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cleveland Clinic, Cleveland, Ohio, United States
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   Atsuro Uchida, Alcon Japan Ltd (F), Betty J. Powers Retina Research Fellowship (F); Julie Clark, Novartis Pharmaceuticals Corporation (E); Robert Zahid, Novartis Pharmaceuticals Corporation (E); Natalia Figueiredo, None; Leina Lunasco, None; Thuy Le, None; Jamie Reese, None; Xiang Yi Meng, Novartis Pharmaceuticals Corporation (E); Sunil Srivastava, None; Justis Ehlers, Aerpio (C), Aerpio (F), Alcon (C), Alcon (F), Alimera (C), Allergan (C), Bioptigen/Leica (P), Genentech (F), he Betty Powers Optical Coherence Tomography Research Fund (F), Leica/Bioptigen (C), NIH/NEI K23-EY022947-01A1 (F), NIH/NEI R34-EY029308 (F), Novartis (C), Novartis (F), Novartis Pharmaceuticals Corporation (F), Ohio Department of Development TECH-13-059 (F), Regeneron (F), Santen (C), The Norman C. and Donna L. Harbert Endowed Chair Fund (F), The Tom and Maryanne Wagner Advanced Imaging Research Fund (F), The Tony and Leona Campane Image-Guided Surgery and Advanced Image Analysis Research Fund (F), Thrombogenics (C), Thrombogenics (F), Zeiss (C), Zeiss (F)
  • Footnotes
    Support  Funded by Novartis Pharmaceuticals
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2546. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Atsuro Uchida, Julie Clark, Robert Zahid, Natalia Albuquerque Lucena Figueiredo, Leina Lunasco, Thuy Le, Jamie Reese, Xiang Yi Meng, Sunil K Srivastava, Justis Ehlers; Longitudinal Sub-Retinal Pigment Epithelium Disease Burden Assessment in Neovascular Age-Related Macular Degeneration: Results from the OSPREY Study. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2546.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Disease burden in the sub-retinal pigment epithelium (sub-RPE) compartment (e.g., pigment epithelial detachments, choroidal neovascular tissue, drusen) is still challenging area of assessment for treatment response and disease outcomes. This analysis utilizes volumetric assessment of the sub-RPE compartment through multi-layer segmentation assessment to evaluate the longitudinal response of the sub-RPE disease burden in nAMD treated with brolucizumab or aflibercept in the OSPREY trial.

Methods : The OSPREY trial is a phase 2, randomized, double-masked, active-controlled, 56-week study comparing brolucizumab 6 mg and aflibercept 2 mg in nAMD. After the initial loading phase, both groups received q8w dosing until Week 40, after which the brolucizumab group was extended to q12w dosing until Week 56, while the aflibercept group was maintained on q8w dosing. SD-OCT scans for each timepoint were uploaded to a novel software platform for multi-layer volumetric assessment. Total sub-RPE volume (mm3), which is defined as the total volume between the RPE and Bruch’s membrane across the macular cube, was quantified. Statistical analyses were conducted for hypothesis generation without adjustment for multiple comparisons.

Results : At baseline, the total sub-RPE volumetric disease burden was 0.92mm3 and 0.79mm3 for the brolucizumab and aflibercept groups, respectively. Following treatment, the sub-RPE disease burden volume decreased significantly for both groups (P<0.05 vs baseline, at each timepoint for each group). Brolucizumab and aflibercept subjects demonstrated mean volume changes of -0.17mm3 and -0.10mm3 at Week 4, -0.20mm3 and -0.11mm3 at Week 40, and -0.20mm3 and -0.12mm3 at Week 56, respectively. Mean percentage changes in volume were -11.83% and -7.90% at Week 4, -14.12% and -7.63% at Week 40, and -14.49% and -8.26% at Week 56 for brolucizumab and aflibercept patients, respectively.

Conclusions : This analysis provides a unique assessment of the sub-RPE compartment. This assessment demonstrates significant reduction in sub-RPE disease burden following brolucizumab and aflibercept treatment. This reduction continues in the brolucizumab group following interval extension to 12 weeks.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×